Journal
NEURON
Volume 77, Issue 2, Pages 243-250Publisher
CELL PRESS
DOI: 10.1016/j.neuron.2012.01.034
Keywords
-
Categories
Funding
- FRAXA
- NIMH
- NICHD
- Simons Foundation
Ask authors/readers for more resources
Many neuropsychiatric symptoms of fragile X syndrome (FXS) are believed to be a consequence of altered regulation of protein synthesis at synapses. We discovered that lovastatin, a drug that is widely prescribed for the treatment of high cholesterol, can correct excess hippocampal protein synthesis in the mouse model of FXS and can prevent one of the robust functional consequences of increased protein synthesis in FXS, epileptogenesis. These data suggest that lovastatin is potentially disease modifying and could be a viable prophylactic treatment for epileptogenesis in FXS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available